Quest Diagnostics (DGX) Rating Reiterated by Craig Hallum

Quest Diagnostics (NYSE:DGX)‘s stock had its “hold” rating reaffirmed by Craig Hallum in a report issued on Friday, The Fly reports. They presently have a $94.00 target price on the medical research company’s stock. Craig Hallum’s price target would indicate a potential upside of 6.13% from the stock’s current price.

Several other brokerages also recently weighed in on DGX. ValuEngine downgraded Quest Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday. Canaccord Genuity reaffirmed a “buy” rating and issued a $98.00 target price on shares of Quest Diagnostics in a research report on Friday. Credit Suisse Group decreased their target price on Quest Diagnostics from $121.00 to $103.00 and set an “outperform” rating for the company in a research report on Friday. Goldman Sachs Group downgraded Quest Diagnostics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $110.00 to $90.00 in a research report on Friday. Finally, Citigroup decreased their target price on Quest Diagnostics from $112.00 to $104.00 and set a “neutral” rating for the company in a research report on Wednesday, October 24th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $105.67.

DGX stock opened at $88.57 on Friday. Quest Diagnostics has a 12-month low of $85.56 and a 12-month high of $116.49. The company has a quick ratio of 1.09, a current ratio of 1.15 and a debt-to-equity ratio of 0.63. The stock has a market cap of $11.97 billion, a price-to-earnings ratio of 16.40, a PEG ratio of 1.60 and a beta of 0.90.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.68 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.68. Quest Diagnostics had a return on equity of 15.71% and a net margin of 11.30%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. The firm’s quarterly revenue was up 1.8% compared to the same quarter last year. On average, research analysts anticipate that Quest Diagnostics will post 6.5 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Quest Diagnostics by 8,866.7% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,076 shares of the medical research company’s stock worth $118,000 after acquiring an additional 1,064 shares in the last quarter. Fort L.P. acquired a new position in shares of Quest Diagnostics in the second quarter worth about $121,000. Capital Advisors Ltd. LLC acquired a new position in shares of Quest Diagnostics in the third quarter worth about $123,000. Flagship Harbor Advisors LLC acquired a new position in shares of Quest Diagnostics in the second quarter worth about $126,000. Finally, Belpointe Asset Management LLC acquired a new position in shares of Quest Diagnostics in the third quarter worth about $125,000. Institutional investors and hedge funds own 86.00% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Read More: Momentum Indicator: Relative Strength Index

The Fly

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit